Table 2.
Demographic and clinical characteristics of the ovarian cancer survivors.
| Items | Groups | |||
|---|---|---|---|---|
| Total (n = 27) | COG (n = 15) | EXG (n = 12) | p | |
| Age (y) | 51.07 ± 5.68 | 50.60 ± 5.83 | 51.67 ± 5.68 | 0.548 |
| Height (cm) | 155.74 ± 4.08 | 155.80 ± 3.10 | 155.67 ± 5.21 | 0.981 |
| Body weight (kg) | 57.26 ± 9.76 | 57.14 ± 6.13 | 57.41 ± 13.33 | 0.486 |
| Body mass index (kg/m2) | 23.60 ± 3.78 | 23.61 ± 3.03 | 23.59 ± 4.70 | 0.829 |
| Married, n (%) | 23 (85.2%) | 13 (86.7%) | 10 (83.3%) | 0.905 |
| Employed, n (%) | 8 (29.6%) | 6 (40.0%) | 2 (16.7%) | 0.323 |
| Current smoker, n | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | - |
| Medications’ number | 1.85 ± 0.99 | 1.87 ± 1.13 | 1.83 ± 0.83 | 0.867 |
| Supplements’ number | 1.89 ± 0.64 | 1.87 ± 0.64 | 1.92 ± 0.67 | 0.867 |
| Comorbidities’ number | 2.58 ± 0.97 | 2.40 ± 0.98 | 2.83 ± 0.94 | 0.236 |
| Ovarian cancer diagnosed year | 4.06 ± 0.49 | 4.12 ± 0.47 | 3.99 ± 0.52 | 0.373 |
| Primary cytoreductive surgery (month) | 46.40 ± 5.93 | 46.18 ± 6.00 | 46.67 ± 6.20 | 1.000 |
| Primary cytoreductive surgery, n (%) | 20 (74.1%) | 11 (73.3%) | 9 (75.0%) | - |
| Interval debulking surgery (month) | 44.71 ± 6.02 | 43.75 ± 5.62 | 46.00 ± 7.55 | 0.857 |
| Interval debulking surgery, n (%) | 7 (25.9%) | 4 (26.7%) | 3 (25.0%) | - |
| Lymph node metastasis, n (%) | 5 (18.5%) | 2 (13.3%) | 3 (25.0%) | 0.614 |
| Organ metastasis, n (%) | 3 (11.1%) | 1 (6.7%) | 2 (16.7%) | 0.683 |
| Other ovarian cancer-related treatment | - | |||
| Surgery, n (%) | 22 (81.5%) | 12 (80.0%) | 10 (83.3%) | 0.905 |
| Radiation therapy, n (%) | 17 (63.0%) | 10 (66.7%) | 7 (58.3%) | 0.719 |
| Chemotherapy, n (%) | 22 (81.5%) | 12 (80.0%) | 10 (83.3%) | 0.905 |
All data represent mean ± standard deviation or number (%). COG, control group; EXG, exercise group.